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amathibodi Hospital, Mahidol University, Bangkok, ThailandA B S T R A C TObjectives: To measure health utility by using the EuroQol five-dimen-
sional questionnaire (EQ-5D) in Thai patients undergoing peritoneal dial-
ysis (PD) and to examine the relationship between the EQ-5D and patient
characteristics including sociodemographic and clinical data and end-
stage renal disease symptoms. Methods: This was a cross-sectional
study. About 10 to 12 patients undergoing PD were randomly selected
from each of the 10 hospitals located in every part of Thailand. Face-to-
face interviews were conducted from October 2008 to February 2009. Pa-
tients assessed their health status by using five domains and a visual
analogue scale. The EQ-5D scorewas calculated on the basis of responses
to five domains by using the Thai value set. Multiple regression analyses
using a stepwise method were employed to model the associations be-
tween the EQ-5D score, the VAS score, and patient characteristics.
Results: The patients’ mean age was 42.2  13.8 years; 53% were male.
Themean PD durationwas 7.4 6.0months. Themean EQ-5D and visual
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doi:10.1016/j.jval.2011.11.005analogue scale scores were 0.65  0.23 and 0.65  0.26, respectively. The
EQ-5D score was higher than that obtained from a meta-analysis study
(0.58). The multivariate regression model showed that education, work
status, diabetes, and end-stage renal disease symptoms were significant
predictors of the EQ-5D score. The significant predictors of the VAS score
includedwork status, albumin level, use of erythropoietin, and end-stage
renal disease symptoms. Conclusions: This Thai PD sample yielded
higher EQ-5Dscores thandidother PDpopulations. To improve thehealth
utility of Thai patients undergoing PD, the significant factors should be
addressed. Because our PD sample had a short PD duration, their long-
term health utility should be evaluated in future research.
Keywords: EQ-5D, health utility, peritoneal dialysis, visual analogue scale.
Copyright © 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
End-stage renal disease (ESRD) is an important public health prob-
lemworldwide including Thailand, with the current incidence be-
ing 10,000 patients per year [1]. Renal replacement therapy is es-
sential to patients with ESRD. The three major renal replacement
therapymodalities are hemodialysis (HD), peritoneal dialysis (PD),
and kidney transplantation. Because of the inadequate number of
donated kidneys, dialysis, especially HD, is the main therapy for
ERSD. The annual cost of HD, however, is about US$12,100 per year
or US$18,500 per quality-adjusted life-year (QALY), which is
greater than three times the annual income per capita of Thai
people [2]. In addition, in 2007, PD was proved to be more cost-
effective than HD [3]. Thus, the Thai government has financially
supported patients with ESRD undergoing PD under the universal
health-care coverage through the National Health Security Office
since 2008. It is called the PD-first policy. By the time of this study,
there were about 1000 patients with ESRD undergoing PDwho had
registered with the National Health Security Office [4].
Several studies have demonstrated that patients with ESRD ex-
perience reduced health-related quality of life (HRQOL) [5–7]. Thus, it
is crucial tomeasure theirHRQOL.BesidesdeterioratedHRQOL,ESRD
has a high cost of treatment, and so developing a cost-effective in-
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Published by Elsevier Inc.tervention in preventing and treating ESRD is needed. Health utility
(HU) is HRQOL that can be incorporated into cost-effectiveness anal-
ysis or cost-utility analysis whose most commonly used outcomes
are QALYs gained [8,9]. The QALY is a measure of life expectancy
weighted by an HU score, which is usually between 0 (death) and 1
(full health). Therefore, HU has both advantages: measuring HRQOL
anduse for economic evaluation inhealth care. Little is known, how-
ever, about theHUof Thai patients undergoing PD. The EuroQol five-
dimensional questionnaire (EQ-5D) is the most frequently used HU
instrument for calculating QALYs based on the actualmeasurement
of patients’ HRQOL [10]. Because the EQ-5D has shown good psycho-
metric properties in Thai patients [11,12], it is the recommended HU
method in Thailand [13]. Therefore, the present study was aimed at
measuring HU by using the EQ-5D in Thai patients undergoing PD
and to examine the factors related to it.
Methods
Participants and procedures
This study was a cross-sectional study. Of the 24 hospitals regis-
teredwith theNational Health Security Office, 10 hospitals located
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in the study. A simple random sampling was used to select 12
patients undergoing PD from each of the 10 hospitals. Patients
eligible for the study had to be willing to participate in the study
and be able to understand the Thai language. Of the 120 ap-
proached, there were 102 eligible patients. Face-to-face interviews
were conducted by a trained interviewer at the 10 hospitals from
October 2008 to February 2009. Medical records were reviewed for
clinical data. This studywas approved by the Ethical Committee of
Ramathibodi Hospital. The face-to-face interview included the fol-
lowing measures.
EQ-5D
The EQ-5D has five domains: mobility, self-care, usual activity,
pain/discomfort, and anxiety/depression. Each domain has three
levels: no problems, some problems, andmajor problems. Patients
were asked to select the level that best described their current
health today for each of the five domains. Responses to the five
domains were expressed as an EQ-5D score originally using the
value set from the United Kingdom [14]. Because there is a Thai
value set available [15], it was employed to calculate the EQ-5D
score in this study. The resulting EQ-5D score was between 0.45
and 1.00, where 1.00 and 0 represent perfect health and death,
respectively, with negative values indicating states worse than
death. In this study, the Cronbach’s alpha value (an indicator of
internal consistency reliability) of the EQ-5D was 0.77, above the
acceptable value of 0.70 [16].
The second part of the EQ-5D is a visual analogue scale (VAS).
Table 1 – Patient characteristics (N = 102).
Characteristics Value
Age (y)
Mean  SD 42.2  13.8
Median (range) 44.5 (10–70)
Gender (male), n (%) 54 (53)
Number of years of education
Mean  SD 6.6  3.6
Median (range) 6 (0–16)
Employment status (employed), n (%) 43 (42)
Hypertension (yes), n (%) 86 (84)
Diabetes (yes), n (%) 31 (30)
Number of comorbidities
Mean  SD 1.5  0.8
Median (range) 1 (0–4)
PD duration (mo)
Mean  SD 7.4  6.0
Median (range) 7.2 (0.4–48.7)
Serum creatinine level (mg/dl)
Mean  SD 10.8  3.9
Median (range) 10.5 (3.6–21.3)
Hemoglobin level (g/dl)
Mean  SD 8.7  2.1
Median (range) 8.4 (4.4–13.7)
Albumin level (g/L)
Mean  SD 3.2  0.5
Median (range) 3.2 (2.0–4.5)
Erythropoietin units per week
Mean  SD 1,914  2,061
Median (range) 0 (0–8,000)
ESRD symptoms
Mean  SD 73.43  20.70
Median (range) 79.17 (4.17–100)
PD, peritoneal dialysis; SD, standard deviation.or the VAS, the patients were presented with a vertical line withend points of “worst imaginable health” at 0 and “best imaginable
health” at 100. The respondents were asked to mark the point on
the scale that corresponded to their rating of their current health
state. The VAS scorewas obtained by dividing the numbermarked
on the scale by 100, which is between 0.00 and 1.00.
ESRD symptoms
A list of 12 symptomswas derived from theKidneyDiseaseQuality
of Life questionnaire, one of the most commonly used disease-
specific HRQOLmeasures in ESRD [17]. The 12 symptoms are sore-
ness in your muscles, chest pain, cramps, itchy skin, dry skin,
shortness of breath, faintness or dizziness, lack of appetite, feeling
washed out, numbness in hands and feet, nausea or upset stom-
ach, and problems with your catheter site. The patients were
asked to indicate howmuch these symptoms/problems had both-
ered them in the past 4 weeks. All items were scored on a five-
point scale, where 100 not at all bothered, 75 somewhat both-
red, 50moderately bothered, 25 verymuch bothered, and 0
extremely bothered. The average score ranged from0 to 100where
a higher summary score indicated better HRQOL. The Cronbach’s
alpha value of the scalewas 0.89, greater than the acceptable value
of 0.70 [16].
Statistical analysis
To summarize patient characteristics and descriptive statistics,
percentages and frequencies were used for categorical variables,
and means, standard deviations, medians, and range (minimum–
maximum) were calculated for continuous variables. Chi-square
tests were performed to assess the relationship between the fre-
Table 2 – Descriptive statistics of EQ-5D domains, the
EQ-5D score, and the VAS score.
Domain Frequency (%)
Mobility
No problem walking 83 (81)
Some problem walking 19 (19)
Confined to bed 0
Self-care
No problem 82 (80)
Some problems washing or dressing self 20 (20)
Unable to wash or dress self 0
Usual activities (e.g., work, study,
housework, family or leisure
activities)
No problem 38 (37)
Some problem 59 (58)
Unable to perform 5 (5)
Pain/discomfort
No pain or discomfort 34 (33)
Moderate 61 (60)
Extreme 7 (7)
Anxiety/depression
Not anxious or depressed 47 (46)
Moderate 50 (49)
Extreme 5 (5)
EQ-5D scores
Mean  SD 0.65  0.23
Median (range) 0.63 (0.022 to 1.00)
VAS scores
Mean  SD 0.65  0.26
Median (range) 0.70 (0.0–1.00)
EQ-5D, EuroQol five-dimensional questionnaire; SD, standard devi-
ation; VAS, visual analogue scale.
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patient characteristics. Independent t tests were carried out to
examine the associations between the EQ-5D score, the VAS score,
and patient characteristics. The patient characteristics are those
presented in Table 1. If the patient characteristics were continu-
ous variables, theywere divided into two groups by usingmedians
for both chi-square tests and independent t tests. To adjust for all
covariates, multiple regression analyses using a stepwise method
were used tomodel the associations between the EQ-5D score, the
VAS score, and patient characteristics. Collinearity problemswere
also checked, but none of them were found (data not shown). P
values of less than 0.05 were considered significant. All analyses
were performed by using SPSS version 17.0 (SPSS, Inc., Bangkok,
Thailand).
Table 3 – EQ-5D domains and patient characteristics.
Mobility Self-car
% of any
problems
P
value
% of any
problems
Age (y)
44.5 3.9 0.000* 11.7
44.5 33.3 27.4
Gender
Female 27.1 0.039† 22.9
Male 11.1 16.7
Education (y)
6 35.6 0.000* 33.3
6 5.3 8.8
Work status
Unemployed 25.4 0.039† 25.4
Employed 9.0 11.6
Hypertension
No 25.0 0.476 18.8
Yes 17.4 19.8
Diabetes
No 5.6 0.000* 12.7
Yes 48.4 35.5
Number of comorbidities
1 10.9 0.030† 12.7
1 27.7 27.7
PD duration (mo)
7.2 23.5 0.204 15.7
7.2 13.7 23.5
Serum creatinine level (mg/dl)
10.50 22.5 0.116 23.4
10.50 12.8 10.6
Hemoglobin level (g/dl)
8.40 22.4 0.505 26.5
8.40 17.0 10.6
Albumin level (g/L)
3.20 26.9 0.036† 19.2
3.20 10.4 16.7
Use of erythropoietin
No 19.2 0.873 21.2
Yes 18.0 18.0
ESRD symptoms
79.17 25.4 0.055 27.3
79.17 10.6 10.6
EQ-5D, EuroQol five-dimensional questionnaire; ESRD, end-stage ren
* P  0.01.
† P  0.05.Results
Patient characteristics
The patients’ mean age was 42.2  13.8 years, and 53% of the
patientsweremale. The average number of years of educationwas
6.6  3.6 years. Forty-two percent of the patients were employed.
The majority of the sample (84%) had hypertension, and 30% had
diabetes. The average number of comorbidities was 1.5  0.8. The
mean duration of undergoing PD was 7.4  6.0 months. Clinical
ata (mean SD) were as follows: serum creatinine level 10.8
3.9 mg/dl, hemoglobin level  8.7 2.1 g/dl, albumin level  3.2
0.5 g/L, and erythropoietin units per week  1914  2061. The
average ESRD symptoms were 73.43  20.70 (Table 1).
Usual activities Pain/discomfort Anxiety/
depression
e
% of any
problems
P
value
% of any
problems
P
value
% of any
problems
P
value
† 56.9 0.051 66.7 0.488 60.8 0.089
68.6 66.7 47.0
62.5 0.828 68.8 0.490 54.2 0.942
63.0 64.8 53.7
* 71.1 0.111 71.1 0.273 51.1 0.173
56.1 63.2 56.1
69.5 0.193 71.1 0.508 57.6 0.397
53.5 60.5 48.8
43.8 0.195 81.2 0.376 31.2 0.118
66.3 69.0 58.1
* 59.1 0.036† 64.8 0.678 47.9 0.019†
71.0 71.0 67.7
54.5 0.082 67.3 0.347 45.4 0.087
72.3 66.0 63.8
54.9 0.196 60.8 0.367 56.9 0.701
70.6 72.5 51.0
70.2 0.132 68.1 0.652 55.3 0.856
53.2 66.0 53.2
† 69.4 0.591 65.3 0.153 57.1 0.773
61.7 72.3 53.2
65.4 0.419 65.4 0.671 50.0 0.230
60.4 68.7 58.3
63.5 0.915 69.2 0.832 55.8 0.778
62.0 64.0 52.0
† 80.0 0.000* 87.3 0.000* 70.9 0.000*
42.6 42.6 34.0
ease; PD, peritoneal dialysis.e
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and the VAS score
About 80% of the patients in the sample stated that they had no
problem with mobility and self-care, whereas 20% had some of
problems. Approximately 60% reported that they had some prob-
lems doing usual activities and had pain or discomfort. About 50%
had anxiety or depression. The mean EQ-5D and VAS scores were
0.65  0.23 and 0.65  0.26, respectively (Table 2).
Relationship between the five domains of the EQ-5D and
patient characteristics
The frequencies of any problem responses for mobility were sig-
nificantly higher in those of an older age (P  0.01), females (P 
0.05), thosewith lower education (P 0.01), unemployed (P 0.05),
those with diabetes (P  0.01), those with a higher number of co-
Table 4 – The EQ-5D score, the VAS score, and patient char
EQ-5D s
Mean  SD
Age (y)
44.5 0.71  0.20
44.5 0.59  0.24
Gender
Female 0.66  0.24
Male 0.64  0.22
Education (y)
6 0.58  0.25
6 0.71  0.20
Work status
Unemployed 0.60  0.21
Employed 0.71  0.25
Hypertension
No 0.64  0.20
Yes 0.65  0.24
Diabetes
No 0.71  0.21
Yes 0.52  0.24
Number of comorbidities
1 0.70  0.20
1 0.59  0.25
PD duration (mo)
7.2 0.67  0.26
7.2 0.63  0.24
Serum creatinine level (mg/dl)
10.50 0.63  0.22
10.50 0.68  0.24
Hemoglobin level (g/dl)
8.40 0.63  0.24
8.40 0.66  0.21
Albumin level (g/L)
3.20 0.64  0.26
3.20 0.67  0.20
Use of erythropoietin
No 0.64  0.24
Yes 0.66  0.23
ESRD symptoms
79.17 0.55  0.23
79.17 0.77  0.18
EQ-5D, EuroQol five-dimensional (EQ-5D) questionnaire; ESRD, end-
visual analogue scale.
* P  0.01.
† P  0.05.morbidities (P  0.05), and those with a lower albumin level (P 
0.05). The older age group (P 0.05) and the lower education group
(P  0.01) also yielded a higher number of any problems in self-
are. The frequencies of any problems were statistically signifi-
antly higher for every domain except pain/discomfort in patients
ith diabetes (P 0.678). The patients with more ESRD symptoms
ho were undergoing PD had greater problems with self-care (P
.05), usual activities (P  0.01), pain/discomfort (P  0.01), and
nxiety/depression (P 0.01). Lower hemoglobin level was related
o greater problems with self-care (P  0.05) (Table 3).
Association between the EQ-5D score, the VAS score, and
patient characteristics
Higher EQ-5D scores were significantly associated with younger
ages (P  0.01), higher education (P  0.01), employed status (P 
ristics.
VAS score
P value Mean  SD P value
0.006* 0.67  0.25 0.377
0.63  0.28
0.554 0.69  0.26 0.183
0.62  0.27
0.003* 0.64  0.29 0.688
0.66  0.24
0.018† 0.63  0.30 0.270
0.68  0.21
0.920 0.69  0.23 0.465
0.64  0.27
0.000* 0.68  0.24 0.122
0.59  0.30
0.012† 0.68  0.23 0.188
0.61  0.30
0.398 0.65  0.28 0.840
0.64  0.25
0.242 0.63  0.29 0.453
0.67  0.24
0.610 0.62  0.26 0.235
0.68  0.26
0.499 0.68  0.27 0.265
0.62  0.26
0.705 0.58  0.27 0.015*
0.71  0.22
0.000* 0.59  0.27 0.020†
0.71  0.24
renal disease; PD, peritoneal dialysis; SD, standard deviation; VAS,acte
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bidities (P 0.05), and fewer ESRD symptoms (P 0.01). There was
statistically significant relationship between the VAS score and
he use of erythropoietin and ESRD symptoms (both P  0.05)
Table 4).
Multiple regression models of the EQ-5D score and the VAS
score
Themultiple regression equation showed that the significant pre-
dictors of the EQ-5D score included education (P  0.05), work
status (P 0.01), diabetes (P 0.01), and ESRD symptoms (P 0.01).
he adjusted R2 was about 54% (F 27.00; P 0.001). As for theVAS
score, the significant predictors werework status (P 0.05), albumin
level (P 0.05), use of erythropoietin (P 0.01), and ESRD symptoms
(p  0.01). The adjusted R2 was about 20% (F  6.60; P  0.001)
(Table 5).
Discussion
The purposes of the present study were tomeasure the HU by using
the EQ-5D in Thai patients undergoing PD and to investigate the re-
lationship between EQ-5D and VAS scores and sociodemographic
and clinical data. To the best of our best knowledge, it was the first
time that HU in Thai patients undergoing PD was reported in the
international literature. It was also the first study to use the Thai
value set to calculate EQ-5D scores in a sample of Thai patients.
Both mean EQ-5D and VAS scores were 0.65, meaning that the
Thai patients undergoing PD rated their current health at approx-
imately 65% of perfect health. This score was also comparable to
that of Thai diabetic patients (0.67) [11]. Compared with the PD
samples of other nations, the Thai PD sample yielded a higher
EQ-5D score, higher than that yielded by a meta-analysis study
(0.58) [18]. In this study, the Thai value set was utilized to estimate
EQ-5D scores, while most studies from the meta-analysis em-
ployed the UK value set. If the UK value set had been used in this
Thai sample, the mean EQ-5D score would have increased from
0.65 to 0.68. Thus, no matter which value set we employed, the
Thai PD sample yielded EQ-5D scores higher than those yielded by
other PD samples. The three possible explanations for this differ-
ence are the following. First, the mean age of Thai patients under-
Table 5 – Relationship between the EQ-5D score, the VAS s
analyses (stepwise method).
Predictors EQ-5D score
Standardized coefficients
Age 0.088
Gender 0.021
Education 0.164
Work status 0.299
Hypertension 0.006
Diabetes 0.243
Comorbidities 0.142
PD duration 0.062
Serum creatinine level 0.009
Hemoglobin level 0.116
Albumin level 0.064
Erythropoietin 0.052
ESRD symptoms 0.585
Adjusted R2 0.542 (F  27.00; P  0.00
EQ-5D, EuroQol five-dimensional (EQ-5D) questionnaire; ESRD, end-s
* P  0.05.
† P  0.01.going PD (42 years) was lower than that of patients from othernations (59 years). Second, the duration of PD of Thai patients
was shorter (0.6 years vs. 1–2 years) because Bakewell and col-
leagues [7] reported that the quality of life of patients undergo-
ing PD declined over time. Third, the difference may have been
due to social desirability because this study used face-to-face
interviews, whereas most studies from the meta-analysis em-
ployed self-administration.
This research found that by using the EQ-5D that HU decreased
because of old age, low education, unemployment, the presence of
diabetes, a higher number of comorbidities, andmore ESRD symp-
toms. The inverse association between HRQOL and age was con-
sistent with the result of Blake et al. [19]. Lower education was
related to poor EQ-5D score, which agrees with the study ofManns
et al. [5]. Similar to other studies [19,20], work statuswas positively
ssociated with HRQOL. The presence of diabetes was associated
ith poor physical health, which was similar to other studies
21,22]. A higher number of cormobidities was associated with
oor HRQOL, which agrees with other studies [5,23]. The negative
relationship between ERSD symptoms and HRQOL was consistent
with the study of Hong et al. [24]. Like the EQ-5D score, higher VAS
scores were associated with fewer ERSD symptoms. In addition,
the present study found that the VAS score had a positive relation-
ship with the use of erythropoietin, which is in keeping with the
review study [25].
After multivariate adjustment, significant predictors of the
EQ-5D score included education, work status, diabetes, and ESRD
symptoms but no correlation occurred for age and the number of
comorbidities. As for the VAS score, the multivariate analysis
showed thatwork status, albumin level, use of erythropoietin, and
ERSD symptoms were significant factors. However, the difference
in variances between the EQ-5D model (54%) and the VAS model
(20%)was large. A possible explanation for this differencewas that
the EQ-5D was easier to understand [12] but the VASmust depend
on a subject’s numeracy or quantitative reasoning skills [26]. If the
patients had little experiencewith rating their health in relation to
numbers, they may poorly perform on the VAS. Interestingly, the
VAS had a correlation with erythropoietin but the EQ-5D did not,
even though the review study showed that higher HRQOL was
related to the use of erythropoietin [25]. A possible explanation for
this is that the EQ-5D measures HRQOL indirectly from the five
domains, whereas the VASmeasures it directly from the patient’s
, and patient characteristics using multivariate regression
VAS score
P value Standardized coefficients P value
0.285 0.082 0.413
0.801 0.140 0.161
0.028* 0.086 0.380
0.000† 0.251 0.013*
0.934 0.066 0.498
0.002† 0.090 0.375
0.115 0.055 0.578
0.406 0.074 0.450
0.917 0.065 0.552
0.123 0.028 0.790
0.390 0.213 0.035*
0.495 0.367 0.001†
0.000† 0.343 0.001†
0.203 (F  6.60; P  0.001)
enal disease; PD, peritoneal dialysis; VAS, visual analogue scale.core
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S84 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 7 9 – S 8 4mobility and self-caremaynot be relevant to the health of patients
undergoing PD. Furthermore, the EQ-5D has the limited response
set of three levels, which may cause less sensitivity to differences
in health between those who used and did not use erythropoietin.
Thus, the VAS more clearly showed the impact of erythropoietin
on the patient’s health status. Surprisingly, the EQ-5D had no re-
lationship and the VAS had a negative association with the albu-
min level. Bilgic and colleagues [27] found that the albumin level
was positively correlated with HRQOL in patients undergoing PD.
A possible reason may be that our PD sample still had poor nutri-
tion (mean albumin level 3.2 g/dl), while the other sample had a
highermean albumin level of 3.8 g/dl. Therefore, the albumin level
could not differentiate the HRQOL of our patients undergoing PD.
A limitation of this study that should be mentioned is that the
adequacy of PD therapy such as Kt/V, an important clinical param-
eter in patients undergoing PD, could not be collected from the
medical records. The reason is that the PD-first policy was just
implemented, and so there were still inadequate numbers of clin-
ical staff to take care of the patients undergoing PD. Thus, most of
these data were not recorded.
In conclusion, this Thai PD sample yielded higher HU mea-
sured with the EQ-5D than did other PD populations. Education,
work status, diabetes, and ESRD symptoms were significant pre-
dictors of the EQ-5D score, and work status, albumin level, use of
erythropoietin, and ESRD symptomswere significant predictors of
the VAS score. To improve the HU of Thai patients undergoing PD,
these factors should be addressed. Because our PD sample had a
short PD duration, the long-termHU should be evaluated in future
research.
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